Literature DB >> 31730835

Viral Infection Increases the Risk of Idiopathic Pulmonary Fibrosis: A Meta-Analysis.

Gaohong Sheng1, Peng Chen2, Yanqiu Wei3, Huihui Yue3, Jiaojiao Chu3, Jianping Zhao3, Yihua Wang4, Wanguang Zhang5, Hui-Lan Zhang6.   

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic lung disease with a poor prognosis. Although many factors have been identified that possibly trigger or aggravate IPF, such as viral infection, the exact cause of IPF remains unclear. Until now, there has been no systematic review to assess the role of viral infection in IPF quantitatively.
OBJECTIVE: This meta-analysis aims to present a collective view on the relationship between viral infection and IPF.
METHODS: We searched studies reporting the effect of viral infection on IPF in the PubMed, Embase, Cochrane Library, Web of Science, and Wiley Online Library databases. We calculated ORs with 95% CIs to assess the risk of virus in IPF. We also estimated statistical heterogeneity by using I2 and Cochran Q tests and publication bias by using the funnel plot, Begg test, Egger test, and trim-and-fill methods. Regression, sensitivity, and subgroup analyses were performed to assess the effects of confounding factors, such as sex and age.
RESULTS: We analyzed 20 case-control studies from 10 countries with 1,287 participants. The pooled OR of all viruses indicated that viral infection could increase the risk of IPF significantly (OR, 3.48; 95% CI, 1.61-7.52; P = .001), but not that of exacerbation of IPF (OR, 0.99; 95% CI, 0.47-2.12; P = .988). All analyzed viruses, including Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpesvirus 7 (HHV-7), and human herpesvirus 8 (HHV-8), were associated with a significant elevation in the risk of IPF, except human herpesvirus 6 (HHV-6).
CONCLUSIONS: The presence of persistent or chronic, but not acute, viral infections, including EBVCMV, HHV-7, and HHV-8, significantly increases the risk of developing IPF, but not exacerbation of IPF. These findings imply that viral infection could be a potential risk factor for IPF. Crown
Copyright © 2019. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  idiopathic pulmonary fibrosis; meta-analysis; viral infection; virus

Mesh:

Year:  2019        PMID: 31730835      PMCID: PMC7214095          DOI: 10.1016/j.chest.2019.10.032

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  48 in total

1.  A mutation in the surfactant protein C gene associated with familial interstitial lung disease.

Authors:  L M Nogee; A E Dunbar; S E Wert; F Askin; A Hamvas; J A Whitsett
Journal:  N Engl J Med       Date:  2001-02-22       Impact factor: 91.245

2.  Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity.

Authors:  Jaime L Peters; Alex J Sutton; David R Jones; Keith R Abrams; Lesley Rushton
Journal:  Stat Med       Date:  2007-11-10       Impact factor: 2.373

3.  Bronchoalveolar lavage fluid findings in patients with chronic hepatitis C virus infection.

Authors:  K Kubo; S Yamaguchi; K Fujimoto; M Hanaoka; M Hayasaka; T Honda; T Sodeyama; K Kiyosawa
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

4.  Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis.

Authors:  R Hubbard; S Lewis; K Richards; I Johnston; J Britton
Journal:  Lancet       Date:  1996-02-03       Impact factor: 79.321

Review 5.  Clinical course and prediction of survival in idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Harold R Collard; Talmadge E King
Journal:  Am J Respir Crit Care Med       Date:  2010-10-08       Impact factor: 21.405

6.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

Review 7.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.

Authors:  Harold R Collard; Christopher J Ryerson; Tamera J Corte; Gisli Jenkins; Yasuhiro Kondoh; David J Lederer; Joyce S Lee; Toby M Maher; Athol U Wells; Katerina M Antoniou; Juergen Behr; Kevin K Brown; Vincent Cottin; Kevin R Flaherty; Junya Fukuoka; David M Hansell; Takeshi Johkoh; Naftali Kaminski; Dong Soon Kim; Martin Kolb; David A Lynch; Jeffrey L Myers; Ganesh Raghu; Luca Richeldi; Hiroyuki Taniguchi; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2016-08-01       Impact factor: 21.405

8.  Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening.

Authors:  Bridget D Stuart; Jungmin Choi; Samir Zaidi; Chao Xing; Brody Holohan; Rui Chen; Mihwa Choi; Pooja Dharwadkar; Fernando Torres; Carlos E Girod; Jonathan Weissler; John Fitzgerald; Corey Kershaw; Julia Klesney-Tait; Yolanda Mageto; Jerry W Shay; Weizhen Ji; Kaya Bilguvar; Shrikant Mane; Richard P Lifton; Christine Kim Garcia
Journal:  Nat Genet       Date:  2015-04-13       Impact factor: 41.307

9.  Pirfenidone improves survival in IPF: results from a real-life study.

Authors:  George A Margaritopoulos; Athina Trachalaki; Athol U Wells; Eirini Vasarmidi; Eleni Bibaki; George Papastratigakis; Stathis Detorakis; Nikos Tzanakis; Katerina M Antoniou
Journal:  BMC Pulm Med       Date:  2018-11-23       Impact factor: 3.317

Review 10.  Genetic studies provide clues on the pathogenesis of idiopathic pulmonary fibrosis.

Authors:  Jonathan A Kropski; William E Lawson; Lisa R Young; Timothy S Blackwell
Journal:  Dis Model Mech       Date:  2013-01       Impact factor: 5.758

View more
  41 in total

1.  The Role of HHV-6 in Idiopathic Pulmonary Fibrosis Remains to Be Determined.

Authors:  Nikolas C Victoria; Xiaofeng Zhou; Bethany B Moore
Journal:  Chest       Date:  2020-06       Impact factor: 9.410

Review 2.  Involvement of 4-hydroxy-2-nonenal in the pathogenesis of pulmonary fibrosis.

Authors:  Edilburga Reyes-Jiménez; Alma Aurora Ramírez-Hernández; Jovito Cesar Santos-Álvarez; Juan Manuel Velázquez-Enríquez; Socorro Pina-Canseco; Rafael Baltiérrez-Hoyos; Verónica Rocío Vásquez-Garzón
Journal:  Mol Cell Biochem       Date:  2021-08-31       Impact factor: 3.396

3.  Detection of residual pulmonary alterations with lung ultrasound and effects on postoperative pulmonary complications for patients with asymptomatic SARS-CoV-2 infection undergoing surgeries.

Authors:  Susana González-Suárez; Antonio Barbara Ferreras; Melissa Caicedo Toro; Macarena Aznar de Legarra
Journal:  BMC Anesthesiol       Date:  2022-06-16       Impact factor: 2.376

4.  Incidence and outcome of post-transplant lymphoproliferative disorders in lung transplant patients: Analysis of ISHLT Registry.

Authors:  Lorenzo Zaffiri; Alex Long; Megan L Neely; Wida S Cherikh; Daniel C Chambers; Laurie D Snyder
Journal:  J Heart Lung Transplant       Date:  2020-06-20       Impact factor: 10.247

5.  miR-21 Exerts Anti-proliferative and Pro-apoptotic Effects in LPS-induced WI-38 Cells via Directly Targeting TIMP3.

Authors:  Jin-Xiu Li; You Li; Tian Xia; Feng-Yan Rong
Journal:  Cell Biochem Biophys       Date:  2021-05-03       Impact factor: 2.194

6.  Molecular Signatures of Idiopathic Pulmonary Fibrosis.

Authors:  Iain R Konigsberg; Raphael Borie; Avram D Walts; Jonathan Cardwell; Mauricio Rojas; Fabian Metzger; Stefanie M Hauck; Tasha E Fingerlin; Ivana V Yang; David A Schwartz
Journal:  Am J Respir Cell Mol Biol       Date:  2021-10       Impact factor: 7.748

7.  SARS-CoV-2 Pathogenesis: Imbalance in the Renin-Angiotensin System Favors Lung Fibrosis.

Authors:  M Victoria Delpino; Jorge Quarleri
Journal:  Front Cell Infect Microbiol       Date:  2020-06-12       Impact factor: 5.293

8.  Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosis.

Authors:  Elmira R Vagapova; Timofey D Lebedev; Vladimir S Prassolov
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

9.  Human umbilical cord mesenchymal stromal cells attenuate pulmonary fibrosis via regulatory T cell through interaction with macrophage.

Authors:  Zan Tang; Junxiao Gao; Jie Wu; Guifang Zeng; Yan Liao; Zhenkun Song; Xiao Liang; Junyuan Hu; Yong Hu; Muyun Liu; Nan Li
Journal:  Stem Cell Res Ther       Date:  2021-07-13       Impact factor: 6.832

10.  Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis.

Authors:  Pengfei Sun; Shuyan Qie; Zongjian Liu; Jizhen Ren; Kun Li; Jianing Xi
Journal:  J Med Virol       Date:  2020-03-11       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.